Reports Interim Phase I/IIa Trial Results for TZ101, a Novel Enzyme Treatment to Enhance Stem Cell Targeting/Engraftment for Improved Cancer Patient Clinical Outcomes SAN ANTONIO, TX DEC 18 2013. America Stem Cell, Inc. (ASC) today announces that it has changed its name to Targazyme, Inc. (www.old.targazyme.com). The new name reflects the company’s family of enzyme products aimed at improving cell targeting and engraftment for better efficacy outcomes in stem cell and regenerative medicine. Phase I/IIa results of Targazyme’s lead product, TZ101, were presented at the American Society of Hematology meeting in New Orleans (Popat et al. Abstract #691, Dec 9).
America Stem Cell, Inc. Announces Presentation of Clinical Data at Upcoming American Society of Hematology (ASH) Meeting
SAN ANTONIO TX DEC 4, 2013. America Stem Cell, Inc. (ASC) today announced that three presentations will be made at the upcoming American Society of Hematology (ASH) meeting in New Orleans, LA December 7-10, 2013 on its lead product, ASC-101. ASC-101 is currently undergoing evaluation in a dual umbilical cord blood transplantation study evaluating ASC-101 in patients with hematologic malignancies and myelodysplastic syndrome at The University of Texas MD Anderson Cancer Center. To date, 16 patients have been transplanted with cord blood that was treated with ASC-101 immediately prior to transplant. On the basis of interim data, ASC received clearance from the U.S. Food and Drug Administration
Circulating Mononuclear Progenitor Cells: Differential Roles for Subpopulations in Repair of Retinal Vascular Injury
Caballero S, Hazra S, Bhatwadekar A, Li Calzi S, Paradisio LJ, Miller LP, Chang L., Kern TS and Grant MB. Circulating Mononuclear Progenitor Cells: Differential Roles for Sub-populations in Repair of Retinal Vascular Injury. Invest Ophthalmol Vis Sci. 2013 Apr 26;54(4):3000-9. doi: 10.1167/iovs.12-10280.
America Stem Cell, Inc. Awarded A Phase I SBIR To Explore The Therapeutic Potential Of Its Platform Technology (ASC-101) With Neural Stem Cells In Multiple Sclerosis Model
SAN ANTONIO, TX JANUARY 7, 2013. America Stem Cell, Inc (ASC) today announced that it has been awarded an Advanced Technology Small Business Innovation Research (SBIR) grant from the National Heart Lung and Blood Institute at the National Institutes of Health. This grant will be led by Dr. Leonard Miller, VP Preclinical Research at ASC, in collaboration with Dr. Larry Sherman at the Oregon National Primate Research Center, Oregon Health & Science University (OHSU). Dr. Sherman’s lab has over 15 years of extensive experience in multiple models of demyelinating diseases such as multiple sclerosis (MS), and in the application of
America Stem Cell, Inc. Awarded a Phase I STTR To Explore The Therapeutic Potential Of Its Platform Technology (ASC-101) With Amniotic Fluid-Derived Stem Cells
SAN ANTONIO, TX SEPTEMBER 17, 2012. America Stem Cell, Inc (ASC) today announced that it has been awarded an Advanced Technology Small Business Technology Transfer Research (STTR) grant from the National Heart Lung and Blood Institute at the National Institutes of Health. This grant will be conducted in collaboration with scientists at the Wake Forest Institute of Regenerative Medicine (WFIRM) in Winston-Salem, NC, and will explore the combination of two technologies: ASC-101 developed by America Stem Cell and amniotic fluid-derived stem cells discovered and pioneered by Dr. Shay Soker and colleagues at WFIRM. We will examine the effect of ASC-101-treated
Robinson SN, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, Shim J, Yang H, Steiner D, Decker WK, Xing D, Shultz LD, Savoldo B, Dotti G, Bollard DM, Miller L, Champlin RE, Shpall EJ and Zweidler-McKay PA. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγnull (NSG) mice. Exp Hematol. 2012 Jun;40(6):445-56. doi: 10.1016/j.exphem.2012.01.015. Epub 2012 Feb 2.
Novel enabling technology to enhance stem cell treatments for cancer patients Orphan designation provides seven–year post approval marketing exclusivity, tax credits, and elimination of FDA prescription drug user fees SAN ANTONIO, Mar. 29, 2011. America Stem Cell, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ASC-101 to improve homing to bone marrow (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation. “The orphan drug status confirms the importance of this new novel treatment approach to improve outcomes for patients with serious, life-threatening cancers and other disorders for which hematopoietic stem
America Stem Cell Inc Awarded “Most Promising Life Science Technology Company” at Rice Alliance Life Science Venture Forum
HOUSTON – September 3, 2010 America Stem Cell Inc, was named the ‘Most Promising’ Life Science company at the 9th Annual Rice Alliance for Technology & Entrepreneurship Life Science Venture Forum in Houston last week. Life Science companies showcased their new ventures for an audience of more than 400 attendees, including investors, venture capitalists, industry representatives, business leaders, advisors/mentors, service providers, and entrepreneurs. Cynthia A. Doerr, M.D., partner, Essex Woodlands Health Ventures said of the presenters, “This is one of the most mature groups of healthcare-related company presentations that I have reviewed in Houston, and I intend to follow their
DARA BioSciences and America Stem Cell Broaden Collaboration
Alachua, FL: America Stem Cell and Florida Biologix team up to get an important cancer therapy to the clinic that can potentially making a life-changing difference for patients with blood-related cancers such as Leukemia, Lymphoma and Myeloma. Florida Biologix is pleased to announce that they have signed a development and manufacturing contract for a Phase I cell therapy product, ASC-101, with America Stem Cell. ASC-101 is a breakthrough human recombinant enzyme technology that increases the efficiency of engraftment in transplantation of cord blood derived stem cells. Exciting in vitro and in vivo experimental results attest to the potential for ASC-101